Marine omega-3 fatty acid supplementation in non-alcoholic fatty liver disease: plasma proteomics in the randomized WELCOME* trial
Marine omega-3 fatty acid supplementation in non-alcoholic fatty liver disease: plasma proteomics in the randomized WELCOME* trial
Summary
Background & aims
Non-alcoholic fatty liver disease (NAFLD) is a liver condition characterised by liver fat accumulation and often considered to be the liver manifestation of metabolic syndrome. The aim of this study was to examine in patients with NAFLD the system-wide effects of treatment with docosahexaenoic acid + eicosapentaenoic acid (DHA + EPA) versus placebo on the plasma proteome.
Methods
Plasma from patients that participated in a 15–18 months randomised, double-blind placebo-controlled trial testing the effects of 4 g DHA + EPA daily was analysed using depletion-free quantitative proteomics.
Results
Bioinformatics interpretation of the proteomic analysis showed that DHA + EPA treatment affected pathways involving blood coagulation, immune/inflammatory response and cholesterol metabolism (p < 0.05). Two key proteins of cardiovascular risk, prothrombin and apolipoprotein B-100, were shown to decrease as a result of DHA + EPA supplementation [Prothrombin: Males DHA + EPA Mean iTRAQ log2ratio (SD) = −0.13 (0.20) p = 0.05, Females DHA + EPA Mean iTRAQ log2ratio (SD) = −0.48 (0.35) p = 0.03; Apo B-100: Males DHA + EPA Mean iTRAQ log2ratio (SD) = −0.24 (0.16) p = 0.01, Females DHA + EPA Mean iTRAQ log2ratio (SD) = −0.15 (0.05) p = 0.02].
Conclusions
Plasma proteomics applied in a randomised, placebo-controlled trial showed that high dose DHA + EPA treatment in patients with NAFLD affects multiple pathways involved in chronic non-communicable diseases.
1952-1955
Manousopoulou, Antigoni
9a5e4e75-cea9-4d0b-91c8-0fa2af02632f
Scorletti, Eleonora
42bb0659-ac67-4a73-bf36-a881fe6c1563
Smith, Deborah
b41c2f97-269c-4a50-ba95-830e823cc7df
Teng, Jie
aa0dac71-baf9-499f-9bd4-593e917c9c8c
Fotopoulos, Miltiadis
05714262-55c5-48a7-af57-397d5dd1cd6a
Roumeliotis, Theodoros I.
f1284c98-b5eb-483e-9416-594c678e62fd
Clough, Geraldine F.
9f19639e-a929-4976-ac35-259f9011c494
Calder, Philip C.
1797e54f-378e-4dcb-80a4-3e30018f07a6
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c
Garbis, Spiros D.
7067fd19-50c9-4d42-9611-f370289470bd
1 August 2019
Manousopoulou, Antigoni
9a5e4e75-cea9-4d0b-91c8-0fa2af02632f
Scorletti, Eleonora
42bb0659-ac67-4a73-bf36-a881fe6c1563
Smith, Deborah
b41c2f97-269c-4a50-ba95-830e823cc7df
Teng, Jie
aa0dac71-baf9-499f-9bd4-593e917c9c8c
Fotopoulos, Miltiadis
05714262-55c5-48a7-af57-397d5dd1cd6a
Roumeliotis, Theodoros I.
f1284c98-b5eb-483e-9416-594c678e62fd
Clough, Geraldine F.
9f19639e-a929-4976-ac35-259f9011c494
Calder, Philip C.
1797e54f-378e-4dcb-80a4-3e30018f07a6
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c
Garbis, Spiros D.
7067fd19-50c9-4d42-9611-f370289470bd
Manousopoulou, Antigoni, Scorletti, Eleonora, Smith, Deborah, Teng, Jie, Fotopoulos, Miltiadis, Roumeliotis, Theodoros I., Clough, Geraldine F., Calder, Philip C., Byrne, Christopher D. and Garbis, Spiros D.
(2019)
Marine omega-3 fatty acid supplementation in non-alcoholic fatty liver disease: plasma proteomics in the randomized WELCOME* trial.
Clinical Nutrition, 38 (4), .
(doi:10.1016/j.clnu.2018.07.037).
Abstract
Summary
Background & aims
Non-alcoholic fatty liver disease (NAFLD) is a liver condition characterised by liver fat accumulation and often considered to be the liver manifestation of metabolic syndrome. The aim of this study was to examine in patients with NAFLD the system-wide effects of treatment with docosahexaenoic acid + eicosapentaenoic acid (DHA + EPA) versus placebo on the plasma proteome.
Methods
Plasma from patients that participated in a 15–18 months randomised, double-blind placebo-controlled trial testing the effects of 4 g DHA + EPA daily was analysed using depletion-free quantitative proteomics.
Results
Bioinformatics interpretation of the proteomic analysis showed that DHA + EPA treatment affected pathways involving blood coagulation, immune/inflammatory response and cholesterol metabolism (p < 0.05). Two key proteins of cardiovascular risk, prothrombin and apolipoprotein B-100, were shown to decrease as a result of DHA + EPA supplementation [Prothrombin: Males DHA + EPA Mean iTRAQ log2ratio (SD) = −0.13 (0.20) p = 0.05, Females DHA + EPA Mean iTRAQ log2ratio (SD) = −0.48 (0.35) p = 0.03; Apo B-100: Males DHA + EPA Mean iTRAQ log2ratio (SD) = −0.24 (0.16) p = 0.01, Females DHA + EPA Mean iTRAQ log2ratio (SD) = −0.15 (0.05) p = 0.02].
Conclusions
Plasma proteomics applied in a randomised, placebo-controlled trial showed that high dose DHA + EPA treatment in patients with NAFLD affects multiple pathways involved in chronic non-communicable diseases.
Text
30 MAY 18 Manousopoulou A et al Clin Nutr clean
- Accepted Manuscript
Image
NAFLD Figure 1
- Accepted Manuscript
Text
Marine omega-3 fatty acid supplementation in non-alcoholic fatty liver disease - Plasma proteomics in the randomized WELCOME trial Clin Nutr Manousopoulou et al 2018
- Version of Record
More information
Accepted/In Press date: 1 August 2018
e-pub ahead of print date: 17 August 2018
Published date: 1 August 2019
Identifiers
Local EPrints ID: 424794
URI: http://eprints.soton.ac.uk/id/eprint/424794
ISSN: 0261-5614
PURE UUID: 8b90cc37-ff78-4738-8eaf-bfc34cc7f2cf
Catalogue record
Date deposited: 05 Oct 2018 11:46
Last modified: 16 Mar 2024 06:58
Export record
Altmetrics
Contributors
Author:
Antigoni Manousopoulou
Author:
Eleonora Scorletti
Author:
Deborah Smith
Author:
Jie Teng
Author:
Miltiadis Fotopoulos
Author:
Theodoros I. Roumeliotis
Author:
Spiros D. Garbis
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
